abiraterone has been researched along with Adenocarcinoma in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.70) | 29.6817 |
| 2010's | 21 (77.78) | 24.3611 |
| 2020's | 5 (18.52) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, N; Azad, A; Benzaghou, F; Carles, J; Chowdhury, S; Kerloeguen, Y; Kimura, A; McGregor, B; Merseburger, AS; Mohamed, N; Oudard, S; Pal, S; Panneerselvam, A; Saad, F; Soares, A; Wang, F | 1 |
| Beriwal, S; Rodríguez-López, JL | 1 |
| Csizmarik, A; Fazekas, T; Grünwald, V; Hadaschik, B; Hüttl, A; Jurányi, Z; Kocsis, Z; Kramer, G; Maj-Hes, A; Nyirády, P; Püllen, L; Sevcenco, S; Shariat, SF; Szarvas, T | 1 |
| Abouassaly, R; Bryk, DJ; Ericson, K; Fascelli, M; Haywood, SC; Khanna, A; Murthy, PB; O'Connor, LP; Yerram, NK | 1 |
| Bundschuh, RA; Dolscheid-Pommerich, RC; Essler, M; Kristiansen, G; Kürpig, S; Mathy, CS; Mayr, T; Meisenheimer, M; Muders, MH; Stoffel-Wagner, B | 1 |
| Fidan, E; Fidan, S; Kocak, G | 1 |
| Burgio, SL; Caroli, P; Casadio, V; Conteduca, V; De Giorgi, U; Gurioli, G; Lolli, C; Matteucci, F; Menna, C; Paganelli, G; Salvi, S; Scarpi, E; Schepisi, G; Testoni, S | 1 |
| Chen, J; Dai, Y; Gao, Q | 1 |
| Akaev, I; Brennan, PA; Chhikara, R; Dabab, N; Fonseca, F; Gomez, RS; Rahimi, S; Rigby, E; Yeoh, CC | 1 |
| Aggarwal, R; Behrens, CR; Bidlingmaier, S; Burlingame, AL; Hann, BC; Lee, NK; Liu, B; Liu, Y; Paris, PL; Premasekharan, G; Seo, Y; Sherbenou, DW; Shuman, MA; Simko, JP; Small, EJ; Su, Y | 1 |
| Bubley, GJ; Calagua, C; Chang, P; Chang, SL; Ellis, WJ; Harshman, LC; Kibel, AS; Lin, DW; Lis, R; McKay, RR; Montgomery, B; Pienta, KJ; Ross, AE; Taplin, ME; Trinh, QD; Wagner, AA; Xie, W; Ye, H; Zhang, Z | 1 |
| Dalgleish, AG; Di Palma, S; Fusi, A; Nathan, K; Patel, N; Powell, B | 1 |
| Bianco, V; Fiaschi, AI; Francini, E; Francini, F; Laera, L; Paganini, G; Perrella, A; Petrioli, R; Roviello, G | 1 |
| Bossi, P; Civelli, E; Cortelazzi, B; Imbimbo, M; Licitra, L; Locati, LD; Perrone, F; Pilotti, S; Potepan, P; Quattrone, P; Rinaldi, G | 1 |
| Amadori, D; Bianchi, E; Burgio, SL; Carretta, E; Conteduca, V; De Giorgi, U; Fabbri, F; Kopf, B; Menna, C; Rossi, L | 1 |
| Antonarakis, ES; Luber, B; Nadal, R; Schweizer, MT; Suzman, DL | 1 |
| Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Roviello, G | 1 |
| Antonarakis, ES; Carducci, MA; Chen, Y; Denmeade, SR; Eisenberger, MA; Lu, C; Luber, B; Luo, J; Nadal, R; Nakazawa, M; Paller, CJ; Wang, H | 1 |
| Aghai, A; Böttcher, R; Burger, H; de Morrée, ES; de Ridder, CM; de Wit, R; Gibson, AA; Mathijssen, RH; Sparreboom, A; van Soest, RJ; van Weerden, WM; Wiemer, EA | 1 |
| Biasco, E; Crucitta, S; Danesi, R; Del Re, M; Derosa, L; Falcone, A; Galli, L; Jenster, GW; Miccoli, M; Orlandini, C; Rofi, E; van Schaik, RH | 1 |
| Ledet, EM; Lewis, BE; Sartor, O; Schiff, JP | 1 |
| Attard, G; Barrett, M; Clark, J; Cooper, CS; de Bono, JS; Dearnaley, D; Dowsett, M; Folkerd, E; Kaye, SB; Lee, G; Martins, V; Parker, C; Raynaud, F; Reid, AH; Settatree, S; Yap, TA | 1 |
| Raghavan, D; Shepard, DR | 1 |
| Shah, BK; Shrestha, S | 1 |
| Cheng, ML; Ryan, CJ | 1 |
3 review(s) available for abiraterone and Adenocarcinoma
| Article | Year |
|---|---|
Contemporary management of advanced prostate cancer: an evolving landscape.
Topics: Adenocarcinoma; Androstenes; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Disease Management; Docetaxel; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Radium; Taxoids; Therapies, Investigational | 2021 |
Innovations in the systemic therapy of prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Delivery Systems; Drugs, Investigational; Humans; Male; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Survival Analysis | 2010 |
Abiraterone acetate for the treatment of prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Androstenes; Androstenols; Antineoplastic Agents; Castration; Disease Progression; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen | 2013 |
4 trial(s) available for abiraterone and Adenocarcinoma
| Article | Year |
|---|---|
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Benzamides; Humans; Immune Checkpoint Inhibitors; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Receptor Protein-Tyrosine Kinases | 2022 |
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Humans; Kallikreins; Leuprolide; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm, Residual; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome; United States | 2019 |
[Recruiting participants - study of therapy of CRPC].
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Biomarkers, Tumor; Disease Progression; Drug Therapy, Combination; Germany; Gonadotropin-Releasing Hormone; Humans; Male; Patient Selection; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2014 |
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androstenes; Androstenols; Castration; Disease Progression; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Treatment Outcome | 2008 |
20 other study(ies) available for abiraterone and Adenocarcinoma
| Article | Year |
|---|---|
Nodal Recurrence From Prostate Adenocarcinoma: Curable or Incurable?
Topics: Adenocarcinoma; Androstenes; Carboxylic Acids; Combined Modality Therapy; Cyclobutanes; Gonadotropin-Releasing Hormone; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Irradiation; Male; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms | 2020 |
Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Androstenes; Antineoplastic Agents; Benzamides; Chromogranin A; Docetaxel; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Phosphopyruvate Hydratase; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Proton Pump Inhibitors; Survival Rate | 2021 |
Antihormone treatment differentially regulates PSA secretion, PSMA expression and
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antigens, Surface; Cell Line, Tumor; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; Glutamate Carboxypeptidase II; Humans; Male; Oligopeptides; PC-3 Cells; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Secretory Pathway | 2021 |
An Unusual Metastasis of Prostate Cancer to Duodenum.
Topics: Adenocarcinoma; Aged; Androstenes; Biopsy; Duodenal Neoplasms; Duodenum; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2016 |
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Chlorine; Choline; Docetaxel; Gene Dosage; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction | 2017 |
Prostate cancer involving bilateral seminal vesicles along with bone and testicular metastases: a case report.
Topics: Adenocarcinoma; Aged; Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Bone Neoplasms; Humans; Male; Neoplasm Grading; Orchiectomy; Physical Examination; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Seminal Vesicles; Testicular Neoplasms; Tomography, X-Ray Computed | 2018 |
Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target.
Topics: Adenocarcinoma; Administration, Oral; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Female; Humans; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Tosyl Compounds | 2018 |
Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
Topics: Adenocarcinoma; Androstenes; Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antibody Affinity; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Female; Humans; Macaca fascicularis; Male; Membrane Cofactor Protein; Neuroendocrine Tumors; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms; Recombinant Fusion Proteins; Signal Transduction; Therapeutics; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
The successful treatment of metastatic androgen receptor-positive tumours of parotid origin with androgen receptor blockade and immunotherapy.
Topics: Adenocarcinoma; Adult; Aged; Androgen Receptor Antagonists; Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bone Neoplasms; Cancer Vaccines; Humans; Male; Nitriles; Parotid Neoplasms; Receptors, Androgen; Tosyl Compounds | 2019 |
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Drug Therapy, Combination; Humans; Male; Mineralocorticoids; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase | 2014 |
Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.
Topics: Adenocarcinoma; Adult; Androgen Antagonists; Androstenes; Androstenols; Anilides; Antineoplastic Agents, Hormonal; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Androgen; Salivary Gland Neoplasms; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate | 2014 |
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Androstenols; Biomarkers, Tumor; Bone Neoplasms; Chromogranin A; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2014 |
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Topics: Adenocarcinoma; Aged; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Androstenes; Androstenols; Antineoplastic Agents; Humans; Kidney Function Tests; Male; Middle Aged; Prostatic Neoplasms; Renal Insufficiency, Chronic | 2014 |
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Topics: Academic Medical Centers; Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Baltimore; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Genetic Predisposition to Disease; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Patient Selection; Phenotype; Phenylthiohydantoin; Predictive Value of Tests; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Risk Factors; RNA, Messenger; Taxoids; Time Factors; Treatment Outcome | 2015 |
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cancer Vaccines; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Singapore; Taxoids; Tissue Extracts | 2015 |
Loss of SLCO1B3 drives taxane resistance in prostate cancer.
Topics: Adenocarcinoma; Androgens; Androstenes; Animals; Antineoplastic Agents, Phytogenic; Benzamides; Biological Transport; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heterografts; Humans; Male; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Organic Anion Transporters, Sodium-Independent; Phenylthiohydantoin; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2016 |
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA | 2017 |
Prostate-specific Antigen Response and Eradication of Androgen Receptor Amplification with High-dose Testosterone in Prostate Cancer.
Topics: Adenocarcinoma; Aged; Androstenes; Antineoplastic Agents, Hormonal; Drug Resistance, Neoplasm; Gene Amplification; Humans; Kallikreins; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Receptors, Androgen; Steroid Synthesis Inhibitors; Testosterone; Treatment Outcome | 2017 |
Durable complete remission with abiraterone in castration resistant metastatic prostate cancer.
Topics: Adenocarcinoma; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Castration; Humans; Lymphatic Metastasis; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction | 2013 |